|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Coexisting intraepithelial carcinoma was detected in seven NECs and only one lesion showed the combination of diffuse RB loss and p16 overexpression.
|
30952735 |
2019 |
|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The tumor suppressor genes RB1 (retinoblastoma) and CDKN2a (cyclin-dependent kinase inhibitor 2a) are critical cell-cycle regulators, but their roles in human cardiomyogenesis remains unclear.
|
30744497 |
2019 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Head and neck HPV-NEC is a rare, aggressive entity that can show mixed small and large cell features and p16 upregulation; p53 and Rb are variable with limited diagnostic utility.
|
30475447 |
2019 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
KRAS<sup>G12D</sup> overexpression in these cells activated transforming growth factor-β signaling and expression of CDKN2B, which, along with CDKN2A, led to cellular senescence and protected cells from KRAS-mediated transformation via inhibition of retinoblastoma phosphorylation.
|
28892048 |
2018 |
|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
There were no CDKN2A alterations found and no correlation of Rb pathway alterations with clinical outcome.
|
30293995 |
2018 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In Astrocytoma, IDH-mutant, PIK3R1 mutations (P = 0.0014) and altered retinoblastoma pathway genes (RB1, CDKN2A, and CDK4) (P = 0.013) were independent predictors of poor survival.
|
29016839 |
2018 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this phase I study, the maximum tolerated dose (MTD) and recommended phase II dose (RP2D), safety, pharmacokinetics (PK), and preliminary activity of single-agent ribociclib were investigated in pediatric patients with neuroblastoma, MRT, or other cyclin D-CDK4/6-INK4-retinoblastoma pathway-altered tumors.<b>Experimental Design:</b> Patients (aged 1-21 years) received escalating once-daily oral doses of ribociclib (3-weeks-on/1-week-off).
|
28432176 |
2017 |
|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In Rb<sup>-/-</sup> p107<sup>-/-</sup> retinoblastomas, somatic copy number alterations (SCNAs) like Mdm2 amplification or Cdkn2a deletion targeting the p53-pathway occur, which is uncommon for human retinoblastoma.
|
27750399 |
2017 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The results showed a decline in the expression of SOX2, P16 and P27 after miR-340 over-expression, whereas we observed an increase in the expression of cyclin A2, CDK2, SOX17, P18, SMAD 4 and RB.
|
27229858 |
2017 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The latter inactivates the tumor suppressor protein retinoblastoma (Rb), which leads to the overexpression of p16(INK4) protein, providing unique Ags for therapeutic HPV-specific cancer vaccination.
|
26851223 |
2016 |
|
Retinoblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In addition, we report for the first time that resistance of KRAS-mutant NSCLCs to MEK inhibitor is, at least partly, due to p16 mutation status, and we described a drug combination that efficiently reactivates the RB tumor suppressor pathway to trigger radiosensitizing effects, apoptosis, and cell-cycle arrest.
|
26728409 |
2016 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Univariate survival analysis revealed that the gene amplification of c-Myc (p = 0.008), Mdm2 (p = 0.020) and the gene deletion of p21 (p = 0.004), p16 (p = 0.015), and Rb1 (p = 0.028) were the independent predictive factor of 5-year OS for patients with TNBC.
|
24096545 |
2014 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The therapeutic targeting of overexpressed p16(ink4a) in the p16(ink4a)-cyclin-Rb pathway may be a useful strategy in the treatment of cervical cancer.
|
24714974 |
2014 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The aim was to explore putative differences in p16(INK) (4a) -retinoblastoma (Rb) pathway and INK4a/ARF methylation between gastric cardia and distal adenocarcinomas.
|
25123601 |
2014 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further provide evidence for an interaction of SATB1 with the retinoblastoma (RB)/E2F pathway downstream of p16.
|
23686316 |
2013 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the other hand, knockdown of p16(ink4a) sensitizes cancer cells to TSC2 knockdown induced cell death in a manner that is likely dependant on serum induction of Cyclin D1 to inactivate the Rb function.
|
23022476 |
2013 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Genes most commonly associated with the process of oncogenesis include: p53 inactivating mutation; hDM2 overexpression; p16 reduced expression; K-/H-RAS activating mutation; PTEN inactivating mutation/deletion; EGFR activating mutation and overexpression; retinoblastoma inactivating mutation and deletion; Cyclin proteins overexpression; CD95 reduced expression; protective BCL-2 proteins overexpression; to name but just a few of such molecules.
|
23974512 |
2013 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This oncogenic p16(INK4A) activity depends on inhibition of CDK4/CDK6, suggesting that in cervical cancer cells where retinoblastoma tumor suppressor is inactivated, CDK4/CDK6 activity needs to be inhibited in order for cells to survive.
|
24046371 |
2013 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DNA microarray and immunohistochemical analyses have shown that most TNBCs fall within the basal-like histological subset of breast cancers, which frequently exhibit inactivation of the retinoblastoma tumor suppressor (Rb) and upregulation of the cyclin-dependent kinase inhibitor p16(INK4a) (p16).
|
21717460 |
2012 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
DNA damage induces cell-intrinsic checkpoints, including p53 and retinoblastoma (RB), as well as upstream regulators (exonuclease 1 (EXO1), ataxia telangiectasia mutated (ATM), ATR, p16(INK4a) and p19(ARF)) and downstream targets (p21, PUMA (p53 upregulated modulator of apoptosis) and sestrins).
|
22914294 |
2012 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate the discrepancy between p14ARF mRNA and protein in retinoblastoma, we examined p14ARF biogenesis.
|
22336108 |
2012 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In an independent cohort, immunohistochemical analyses of RB and p16ink4a revealed an association of RB loss (P = 0.0018) or elevated p16ink4a (P = 0.0253) with pathologic complete response.
|
22811582 |
2012 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Array-based comparative genomic hybridization studies revealed deletions in the CDKN2A locus that include ARF and P16INK4A, both of which encode tumor suppressor proteins, in both human and mouse retinoblastoma.
|
22484813 |
2012 |
|
Retinoblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several molecules such as retinoblastoma and p16 were raised as key factors in tumorigenesis and invasiveness.
|
21565925 |
2011 |
|
Retinoblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The protein and mRNA expressions of cyclin D1, proliferating cell nuclear antigen (PCNA), retinoblastoma (Rb), and p16 were observed with immunofluorescence and RT-PCR, respectively.
|
22139542 |
2011 |